Immune tolerant elastin-like recombinant peptides and methods of use thereof

A recombinant polypeptide and identity technology, applied in the direction of immunoglobulin, peptide/protein components, chemical instruments and methods, etc., can solve the problems of short antibody retention time, local immune checkpoint antibody treatment prospects are not as expected, high exposure, etc.

Pending Publication Date: 2022-06-24
UNIV OF UTAH RES FOUND
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the absence of a delivery system, locally administered antibodies have short retention times in the local area

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune tolerant elastin-like recombinant peptides and methods of use thereof
  • Immune tolerant elastin-like recombinant peptides and methods of use thereof
  • Immune tolerant elastin-like recombinant peptides and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1: Immunotolerant Elastin-Like Polypeptides (ITEPs) for Sustained Local Delivery of Immune Checkpoint Antibodies

[0122] Abstract. To address the challenges associated with the systemic administration of immune checkpoint antibodies, immune-tolerant elastin-like polypeptide (iTEP)-based systems were developed to improve local delivery of immune checkpoint antibodies. Due to the phase-change nature of iTEP, the thermosensitive delivery system can form a sustained-release depot at the injection site. To link the antibody to the depot, the IgG binding domain (IBD) was fused to the iTEP. The results described herein demonstrate that iTEP-IBD polypeptides can prolong antibody release and increase antibody retention time at the local injection site. By controlling the design of the iTEP-IBD polypeptide, the release half-life of the antibody can be fine-tuned from about 17.2 to about 74.9 hours. Using melanoma as a disease model, the results showed that the iTEP-IBD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein are recombinant polypeptides comprising one or more homologous amino acid repeats fused to an IgG binding domain. The recombinant polypeptide can bind to a therapeutic antibody and act as a delivery vehicle to increase the retention time of the therapeutic antibody and reduce systemic-related side effects of the therapeutic antibody. Also disclosed herein are pharmaceutical compositions comprising a recombinant polypeptide that binds to a therapeutic antibody; and methods of administering them to a patient to treat cancer.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of the filing date of US Provisional Application 62 / 890,936, filed August 23, 2019. The contents of this earlier filed application are hereby incorporated by reference in their entirety. [0003] Incorporation of Sequence Listing [0004] This application contains a Sequence Listing submitted in ASCII format through EFS-Web at the time of filing the application, containing the file name 21101_0378P1_Sequence_Listing, which is 65,536 bytes in size, created on May 29, 2020, and incorporated herein by reference in its entirety. Background technique [0005] Immune checkpoint antibodies can be used to treat a variety of cancers. To date, available clinical immune checkpoint antibodies are administered intravenously. Systemic administration of immune checkpoint antibodies can effectively control disseminated tumors. However, when the tumor is localized, systemic antibody therapy is no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/64A61K39/395A61K47/42A61P35/00A61P35/02
CPCA61K38/00C07K2319/31C07K14/315C07K2317/76C07K16/2818A61K2039/505A61K39/395C07K2317/90A61K2300/00C07K7/06A61P35/00C07K2317/73A61K47/64A61K9/0019A61K38/39A61K47/02A61K47/42
Inventor 陈明南汪鹏赵鹏董书芸
Owner UNIV OF UTAH RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap